{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:59:23Z","timestamp":1782302363592,"version":"3.54.5"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>Dupilumab is a fully human monoclonal antibody directed against the interleukin-4 receptor subunit \u03b1, the common chain of the IL-4 and IL-13 receptors. Dupilumab has been demonstrated to be highly effective in the treatment of severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Despite the favorable tolerability of dupilumab, several publications and reviews have reported various adverse events, including conjunctivitis, keratitis, and face and neck treatment-resistant dermatitis, which reduce patients\u2019 quality of life and may necessitate the cancellation of therapy. The current standard of care for severe chronic diseases involves a collaborative approach between the patient and their physician. The majority of patients who respond well to this type of systemic atopic dermatitis (AtD) therapy are reluctant to interrupt dupilumab treatment due to the previously mentioned adverse events. The combination of dupilumab and anti-IgE therapy (omalizumab) may be beneficial for individuals who undergo dupilumab treatment for AtD and experience severe adverse events.<\/jats:p>","DOI":"10.3389\/falgy.2025.1696897","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:34:37Z","timestamp":1768545277000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Series: Combination of dupilumab and omalizumab as a way to reduce dupilumab-associated adverse events in severe atopic dermatitis"],"prefix":"10.3389","volume":"6","author":[{"given":"Daria S.","family":"Fomina","sequence":"first","affiliation":[{"name":"State Budgetary Healthcare Institution of Moscow City \u201cMoscow Clinical Research Center 7 Hospital No. 52 of the Moscow City Health Department\u201d","place":["Moscow, Russia"]},{"name":"Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First 12 Moscow State Medical University of the Ministry of Health of the Russian Federation 13, Sechenovskiy University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga A.","family":"Mukhina","sequence":"additional","affiliation":[{"name":"State Budgetary Healthcare Institution of Moscow City \u201cMoscow Clinical Research Center 7 Hospital No. 52 of the Moscow City Health Department\u201d","place":["Moscow, Russia"]},{"name":"Research Institute of Healthcare Organization and Medical Management of Moscow Department 10 of Healthcare","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta L.","family":"Sedova","sequence":"additional","affiliation":[{"name":"State Budgetary Healthcare Institution of Moscow City \u201cMoscow Clinical Research Center 7 Hospital No. 52 of the Moscow City Health Department\u201d","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina S.","family":"Lebedkina","sequence":"additional","affiliation":[{"name":"State Budgetary Healthcare Institution of Moscow City \u201cMoscow Clinical Research Center 7 Hospital No. 52 of the Moscow City Health Department\u201d","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena N.","family":"Bobrikova","sequence":"additional","affiliation":[{"name":"Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First 12 Moscow State Medical University of the Ministry of Health of the Russian Federation 13, Sechenovskiy University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Karaulov","sequence":"additional","affiliation":[{"name":"Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First 12 Moscow State Medical University of the Ministry of Health of the Russian Federation 13, Sechenovskiy University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana A.","family":"Lysenko","sequence":"additional","affiliation":[{"name":"State Budgetary Healthcare Institution of Moscow City \u201cMoscow Clinical Research Center 7 Hospital No. 52 of the Moscow City Health Department\u201d","place":["Moscow, Russia"]},{"name":"Pirogov Russian National Research Medical University","place":["Moscow, Russia"]},{"name":"Philipps University of Marburg","place":["Marburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Renz","sequence":"additional","affiliation":[{"name":"Research Institute of Healthcare Organization and Medical Management of Moscow Department 10 of Healthcare","place":["Moscow, Russia"]},{"name":"Philipps University of Marburg","place":["Marburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"B1","article-title":"Dupilumab (Dupilumabum) Instructions for Use","year":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jaip.2019.08.050","article-title":"Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma","volume":"8","author":"Corren","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","article-title":"Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE)","volume":"23","author":"Blauvelt","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s12016-022-08934-0","article-title":"Dupilumab-associated adverse events during treatment of allergic diseases","volume":"62","author":"Kychygina","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jaad.2021.09.050","article-title":"Adverse events associated with dupilumab in the World Health Organization pharmacovigilance database","volume":"86","author":"Bettuzzi","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.survophthal.2022.02.002","article-title":"Dupilumab-associated ocular manifestations: a review of clinical presentations and management","volume":"67","author":"Wu","year":"2022","journal-title":"SurvOphthalmol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"103615","DOI":"10.1016\/j.amjoto.2022.103615","article-title":"Adverse events of biological therapy in chronic rhinosinusitis with nasal polyps: a systematic review","volume":"43","author":"Aldajani","year":"2022","journal-title":"Am J Otolaryngol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/ajd.13924","article-title":"Dupilumab-associated ocular surface disease: an interdisciplinary decision framework for prescribers in the Australian setting","volume":"63","author":"Foley","year":"2022","journal-title":"Australas J Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jaad.2020.08.127","article-title":"Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-week results from the Dutch BioDay registry","volume":"84","author":"Ari\u00ebns","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s00105-018-4316-1","article-title":"Interdisziplin\u00e4re handlungsempfehlung bei dupilumab-assoziierten entz\u00fcndlichen augenerkrankungen [Interdisciplinary recommendations for action in dupilumab-related inflammatory eye diseases]","volume":"70","author":"Wohlrab","year":"2019","journal-title":"Hautarzt"},{"key":"B16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40268-019-00288-x","article-title":"A clinician\u2019s guide to the recognition and management of dupilumab-associated conjunctivitis","volume":"19","author":"Agnihotri","year":"2019","journal-title":"Drugs R D"},{"key":"B17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.alit.2020.07.001","article-title":"Dupilumab-resistant facial erythema\u2014dermoscopic, histological and clinical findings of three patients","volume":"70","author":"Nakanishi","year":"2021","journal-title":"AllergolInt"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e27170","DOI":"10.7759\/cureus.27170","article-title":"Dupilumab-associated head and neck dermatitis with ocular involvement in a ten-year-old with atopic dermatitis: a case report and review of the literature","volume":"14","author":"Samia","year":"2022","journal-title":"Cureus"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e2022184","DOI":"10.5826\/dpc.1204a184","article-title":"Dupilumab-associated facial erythema successfully treated with oral ivermectin","volume":"12","author":"Liane","year":"2022","journal-title":"Dermatol Pract Concept"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","article-title":"Facial and neck erythema associated with dupilumab treatment: a systematic review","volume":"84","author":"Jo","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/bjd.21019","article-title":"Dupilumab-associated head and neck dermatitis is associated with elevated pretreatment serum Malassezia-specific IgE: a multicentre, prospective cohort study","volume":"186","author":"Kozera","year":"2022","journal-title":"Br J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3390\/life12020299","article-title":"Study of hypersensitivity to Malassezia furfur in patients with atopic dermatitis with head and neck pattern: is it useful as a biomarker and therapeutic indicator in these patients?","volume":"12","author":"Navarro-Trivi\u00f1o","year":"2022","journal-title":"Life (Basel)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"100707","DOI":"10.1016\/j.waojou.2022.100707","article-title":"Combining biologics targeting eosinophils (IL-5\/IL-5R), IgE, and IL-4\/IL-13 in allergic and inflammatory diseases","volume":"15","author":"Pitlick","year":"2022","journal-title":"World Allergy Organ J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1111\/all.15379","article-title":"Safety of combining biologics in severe asthma: asthma-related and unrelated combinations","volume":"77","author":"Lommatzsch","year":"2022","journal-title":"Allergy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.jaci.2007.08.060","article-title":"Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels","volume":"120","author":"Belloni","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaad.2005.09.030","article-title":"Treatment of recalcitrant atopic dermatitis with omalizumab","volume":"54","author":"Lane","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1365-2230.2012.04438.x","article-title":"Anti-immunoglobulin E in the treatment of refractory atopic dermatitis","volume":"38","author":"Kim","year":"2013","journal-title":"Clin Exp Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/ced.15000","article-title":"Successful treatment of severe recalcitrant vernal keratoconjunctivitis and atopic dermatitis associated with elevated IgE levels with omalizumab","volume":"47","author":"Zengarini","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"480","DOI":"10.23736\/S0392-0488.19.06302-8","article-title":"Omalizumab for atopic dermatitis: evidence for and against its use","volume":"154","author":"Holm","year":"2019","journal-title":"G Ital Dermatol Venereol"},{"key":"B30","article-title":"Omalizumab Instructions for Use","year":""},{"key":"B31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.18176\/jiaci.0614","article-title":"Type 2 inflammation: atopic dermatitis, asthma, and hypereosinophilia successfully treated with dupilumab","volume":"31","author":"Benzecry","year":"2021","journal-title":"J. Investig. Allergol. Clin. Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.alit.2021.11.001","article-title":"Skin microbiome of atopic dermatitis","volume":"71","author":"Koh","year":"2021","journal-title":"Allergol. Int"},{"key":"B33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/myc.13402","article-title":"Dysbiosis of skin mycobiome in atopic dermatitis","volume":"65","author":"Tao","year":"2021","journal-title":"Mycoses"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1046\/j.1365-2222.2000.00937.x","article-title":"Uptake of the yeast Malassezia furfur and its allergenic components by human immature CD1a+ dendritic cells","volume":"30","author":"Buentke","year":"2000","journal-title":"Clin Exp Allergy"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1046\/j.1365-2222.2001.01199.x","article-title":"The allergenic yeast Malassezia furfur induces maturation of human dendritic cells","volume":"31","author":"Buentke","year":"2001","journal-title":"Clin Exp Allergy"},{"key":"B36","doi-asserted-by":"publisher","first-page":"306","DOI":"10.5863\/1551-6776-26.3.306","article-title":"Combination anti-IgE and anti-IL5 therapy in a pediatric patient with severe persistent asthma","volume":"26","author":"Fox","year":"2021","journal-title":"J PediatrPharmacolTher"},{"key":"B37","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/cea.13954","article-title":"Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases","volume":"51","author":"Hamilton","year":"2021","journal-title":"ClinExp Allergy"},{"key":"B38","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/ajd.13743","article-title":"Dual biologic therapy with omalizumab and dupilumab for refractory atopic disease","volume":"63","author":"Arasu","year":"2022","journal-title":"Australas J Dermatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00403-025-04196-w","article-title":"Combined use of omalizumab and dupilumab: safety and efficacy data from a large academic center","volume":"317","author":"Silva","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"611549","DOI":"10.3389\/fimmu.2020.611549","article-title":"Case report: combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid","volume":"11","author":"Jafari","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1696897\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:34:39Z","timestamp":1768545279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1696897\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":40,"alternative-id":["10.3389\/falgy.2025.1696897"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1696897","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"article-number":"1696897"}}